Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Therapy crawled time : 16:20 save search
New Long-Term Data from the CHRYSALIS Study Show Median Progression-Free Survival Not Reached after 33.6 Months of Follow-Up with First-Line Use of RYBREVANT® (amivantamab-vmjw) and Lazertinib Combination Therapy in Patients with Treatment-Naïve EGFR-Mutated Advanced Non-Small Cell Lung Cancer
Published: 2023-06-04 (Crawled : 16:20) - prnewswire.com
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
| Email alert
Add to watchlist
rybrevant lung cancer cell therapy show study
NewAmsterdam Pharma Presents Full Data from Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe as an Adjunct to High-Intensity Statin Therapy at NLA Scientific Sessions 2023
Published: 2023-06-03 (Crawled : 16:20) - globenewswire.com
NAMS | $19.98 2.78% 2.7% 140K
|
n/a
| Email alert
Add to watchlist
pharma sessions trial therapy
AbbVie Announces Late-Breaking Results of Study Evaluating 52-Week Efficacy and Safety of SKYRIZI® (risankizumab) in Plaque Psoriasis Patients With a Prior Suboptimal Response to IL-17 Inhibitor Therapy
Published: 2023-03-18 (Crawled : 16:20) - prnewswire.com
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
| Email alert
Add to watchlist
il-17 skyrizi abbvie psoriasis response therapy results study
New Data Show Superiority of Abbott's TriClip™ Device Compared to Medical Therapy for Tricuspid Regurgitation
Published: 2023-03-04 (Crawled : 16:20) - prnewswire.com
ABT | News | $107.28 1.91% 0.18% 10M
|
Health Technology
| Email alert
Add to watchlist
device medical therapy show
Landmark CLEAR Outcomes Study Demonstrates NEXLETOL® (bempedoic acid) Tablet is the Only LDL-C Lowering Therapy Since Statins to Reduce Hard Ischemic Events in a Broad Population of Both Primary Prevention and Secondary Prevention Patients
Published: 2023-03-04 (Crawled : 16:20) - globenewswire.com
ESPR | $1.94 3.74% 3.61% 7.3M
|
Health Technology
| Email alert
Add to watchlist
nexletol therapy study
BioMarin Announces Stable and Durable Annualized Bleed Control for ROCTAVIAN™ in Largest Phase 3 Gene Therapy Study in Adults with Severe Hemophilia A; 134-Participant Study Met All Primary and Secondary Efficacy Endpoints at 3-Year Analysis
Published: 2023-01-08 (Crawled : 16:20) - prnewswire.com
BMRN | $88.68 -1.54% -1.57% 1.8M
|
Health Technology
| Email alert
Add to watchlist
control therapy study
Poseida Therapeutics Presents Preclinical Data from P-FVIII-101 Gene Therapy for Hemophilia A at the 64th ASH Annual Meeting & Exposition
Published: 2022-12-11 (Crawled : 16:20) - prnewswire.com
PSTX | $2.02 1.0% 0.99% 640K
|
Health Technology
| Email alert
Add to watchlist
fviii-101 preclinical meeting therapeutics therapy
CSL's Novel Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Demonstrates Durable Protection and Sustained Factor IX Activity Levels for People Living with Hemophilia B at 24-Months Post-Treatment
Published: 2022-12-10 (Crawled : 16:20) - prnewswire.com
QURE | $4.68 -0.64% -0.64% 550K
|
Health Technology
| Email alert
Add to watchlist
hemgenix therapy living
Fate Therapeutics Announces Clinical Safety and Activity Data of First-ever iPSC-derived CAR T-cell Therapy at 2022 ASH Annual Meeting
Published: 2022-12-10 (Crawled : 16:20) - globenewswire.com
FATE | $4.795 -4.86% -5.11% 2.7M
|
Health Technology
| Email alert
Add to watchlist
meeting t-cell therapeutics therapy
Janssen Announces Late-Breaking Data from Two Gene Therapy Programs at the American Academy of Ophthalmology 2022 Annual Meeting
Published: 2022-10-01 (Crawled : 16:20) - prnewswire.com
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
| Email alert
Add to watchlist
MGTX | $5.09 1.6% 1.57% 190K
|
Health Technology
| Email alert
Add to watchlist
meeting therapy
Late-Breaking Phase 1/2 Data Demonstrates Safety Profile of Investigational Gene Therapy Botaretigene Sparoparvovec (AAV-RPGR) and Sustained Vision Improvement in Patients with X-Linked Retinitis Pigmentosa (XLRP)
Published: 2022-10-01 (Crawled : 16:20) - globenewswire.com
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
| Email alert
Add to watchlist
MGTX | $5.09 1.6% 1.57% 190K
|
Health Technology
| Email alert
Add to watchlist
therapy
Ocular Therapeutix™ To Present Pre-Clinical Data at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting
Published: 2022-05-03 (Crawled : 16:20) - ocutx.gcs-web.com
OCUL | $5.22 -10.92% -12.26% 9.1M
|
Health Technology
|
| O: 0.25%
H: 0.98%
C: 0.98%
pre-clinical ocular therapy preclinical
Jaguar Animal Health to Host Treatment Forum for Veterinarians About Chemotherapy-Induced Diarrhea (CID) in Dogs on Sunday, March 6th, During the Western Veterinary Conference (WVC) in Las Vegas
Published: 2022-03-01 (Crawled : 16:20) - jaguarhealth.gcs-web.com
JAGX | $0.158 -10.79% -12.09% 30M
|
Health Technology
|
| O: 2.72%
H: 10.71%
C: 0.45%
veterinarians day treatment health conference diarrhea therapy
Results of Novel Clinical Study Show Adults with Moderately to Severely Active Ulcerative Colitis Achieved Higher Rates of Clinical Response, Clinical Remission, and Endoscopic Improvement at 12 Weeks with Guselkumab and Golimumab Combination Therapy Versus Either Monotherapy Alone
Published: 2022-02-19 (Crawled : 16:20) - prnewswire.com
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
| Email alert
Add to watchlist
response active one therapy pons results ulcerative colitis
KalVista Pharmaceuticals to Present Data on Oral On-Demand HAE Therapy KVD900 at AAAAI 2022
Published: 2022-02-02 (Crawled : 16:20) - ir.kalvista.com
KALV | $11.59 0.78% 0.78% 350K
|
Health Technology
|
| O: 0.79%
H: 4.88%
C: -1.4%
kvd900 ema als therapy
AVEO Oncology Presents Three Posters for Tivozanib/Immunotherapy Combinations at the 2022 ASCO GI Cancers Symposium
Published: 2022-01-20 (Crawled : 16:20) - investor.aveooncology.com
AVEO | $15.0 0.0% 0
|
Health Technology
|
| O: 4.69%
H: 0.0%
C: -7.81%
symposium immunotherapy asco therapy cancer
Jaguar Animal Health to Host Treatment Forum for Veterinarians About Chemotherapy-Induced Diarrhea (CID) in Dogs on Sunday, January 16th During the Veterinary Meeting & Expo (VMX) Conference in Orlando, Florida
Published: 2022-01-12 (Crawled : 16:20) - jaguarhealth.gcs-web.com
FNCTF | News | $11.0354 -20.84% 320
|
Communications
|
| O: 0.0%
H: 0.0%
C: 0.0%
JAGX | $0.158 -10.79% -12.09% 30M
|
Health Technology
|
| O: 12.9%
H: 0.0%
C: 0.0%
veterinarians treatment health conference diarrhea therapy
Jaguar Health Announces the Presentation of Findings from the Investigator-Initiated Phase 2 HALT-D Study of Crofelemer for Prevention of Chemotherapy-Induced Diarrhea (CID) in Breast Cancer Patients at San Antonio Breast Cancer Symposium (SABCS 2021)
Published: 2021-12-10 (Crawled : 16:20) - jaguarhealth.gcs-web.com
JAGX | $0.158 -10.79% -12.09% 30M
|
Health Technology
|
| O: 5.22%
H: 0.0%
C: 0.0%
health phase 2 symposium sabcs presentation diarrhea therapy cancer breast cancer initiated crofelemer
Jaguar Health Announces Topline Results of Investigator-Initiated Phase 2 Study of Crofelemer for Prevention of Chemotherapy-Induced Diarrhea (CID) in Breast Cancer Patients
Published: 2021-11-19 (Crawled : 16:20) - jaguarhealth.gcs-web.com
JAGX | $0.158 -10.79% -12.09% 30M
|
Health Technology
|
| O: 1.72%
H: 6.44%
C: 2.37%
phase 2 diarrhea therapy results cancer topline breast cancer initiated crofelemer
Sensei Biotherapeutics Presents Preclinical Data for SNS-101, a pH-Selective Anti-VISTA Antibody, at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
Published: 2021-11-12 (Crawled : 16:20) - investors.senseibio.com
SNSE | $1.03 4.79% 4.57% 24K
|
|
| O: -1.15%
H: 0.0%
C: 0.0%
preclinical immunotherapy therapy cancer antibody iot pre-clinical
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.